Cipher Pharmaceuticals Inc  

(Public, TSE:CPH)   Watch this stock  
Find more results for TSE:DND
-0.37 (-4.64%)
May 31 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 7.36 - 7.95
52 week 4.77 - 13.32
Open 7.88
Vol / Avg. 37,615.00/41,835.00
Mkt cap 207.93M
P/E     -
Div/yield     -
EPS -0.18
Shares 26.17M
Beta 0.56
Inst. own     -
Aug 12, 2016
Q2 2016 Cipher Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 12, 2016
Cipher Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
May 5, 2016
Cipher Pharmaceuticals Inc Annual Shareholders Meeting
May 5, 2016
Q1 2016 Cipher Pharmaceuticals Inc Earnings Release
May 5, 2016
Q1 2016 Cipher Pharmaceuticals Inc Earnings Call
Mar 15, 2016
Cipher Pharmaceuticals Inc at ROTH Conference
Mar 8, 2016
Cipher Pharmaceuticals Inc at Cowen Health Care Conference

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -29.62% 5.14%
Operating margin -12.69% -0.20%
EBITD margin - 14.50%
Return on average assets -9.85% 2.01%
Return on average equity -20.23% 3.27%
Employees 13 -
CDP Score - -


2345 Argentia Road, Suite 100A
+1-905-6025840 (Phone)
+1-905-6020628 (Fax)

Website links


Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Officers and directors

Gerald P. McDole Independent Chairman of the Board
Age: 75
Shawn Patrick O'Brien President, Chief Executive Officer
Norman C. Evans Chief Financial Officer, Secretary
Age: 61
Ralph Bohrer President and General Manager of US Business
Age: 54
Joan Chypyha President, General Manager - Canada
Joseph Pecora President and General Manager - USA
Lorne Markowitz Vice President of Sales and Marketing
Linda Melanie Angaritis Vice President - Global Regulatory Compliance and Quality
Louise Blythe Vice President - Regulatory Affairs
Lynne Cheryl Bulger Vice President - Medical and Clinical Affairs